Our work

Microtracer AMS: Accelerate your clinical development

De-risk and accelerate drug development with TNO’s exclusive auto-combustion-based AMS technology. Each Phase I, first-in-human (FIH) study can be a MIST and Mass Balance study, for faster, economical and accurate drug development. With TNO’s microtracer expertise, drug development becomes a streamlined and targeted process. Our advanced and accurate testing capabilities reduce animal testing and ensure early knowledge of the ADME of a drug in humans.

Swift, effective testing

Current Human ADME studies are often conducted in the late stages of drug development. If and when metabolites are discovered at this late stage, biotech companies face the sometimes-insurmountable challenge of still gaining approval for the drug.

Next-level data collection

TNO’s microtracer technology can deliver simultaneous MIST and Mass Balance data that enables companies to directly identify human metabolites in the development process (Phase 1). With the ability to detect and identify metabolites at such an early development stage, biotech companies no longer need to spend years – and budget – pursuing a drug development that will require additional, excessive toxicology studies.

Game-changing sample preparation

TNO has the unique ability to fully automate blood, plasma, urine or fecal sample analysis by AMS, based on auto-combustion. This differs significantly from the standard gravitization-based approach. Auto-combustion sample preparation allows us to analyse more samples per day, ensures a faster turnover time, and is more economical because it is far less labour-intensive. It also eliminates the need for material recovery and reduces recovery time for human volunteers.

Unique expertise

TNO is the only organisation in Europe with a biomedical Accelerator Mass Spectrometer (AMS) that enables automated CO2 combustion AMS. We were the first to conduct a microdose study using a biopharmaceutical, and also the first to perform a microtracer study in pediatric patients. In a microdosing study, very small doses (< 100 µg) are administered to human volunteers, who do not experience any physical effect from the drug. However, microdosing levels are high enough to be measured at TNO's state-of-the-art AMS facility, and provide real human PK data. This is more valuable than pre-clinical animal testing, and reduces the number of test animals. This is fully in line with TNO's mission to refine, reduce and replace animal testing with faster, more accurate alternatives. Want to know more about how TNO can accelerate and streamline your drug development as early as Phase I? Contact Wouter Vaes for more information.

Downloads
News

Evidence-based interventions to strengthen mental health of children

03 November 2020
As the COVID-19 pandemic continues, access to mental health services in developing countries is more important than ever. Children are overlooked even though investing in child development is an investment... Read more
News

Positive results of market study Flying Food in Rwanda

27 October 2020
This study presents a business opportunity for crickets for human consumption in Rwanda. Consumers show a demand and willingness to include crickets in their diet, because crickets are tasty and nutritious.... Read more
News

Join our SDG-3 workshop on innovative antenatal care during SDG action day 2020

21 September 2020
During the virtual SDG Action Day 2020 on September 25, TNO will organise the international workshop ‘Saving lives at birth, how to realize this goal by shared innovation’. We focus on the innovative approach... Read more

Contact

Dr. Wouter Vaes

  • pharmacokinetics
  • microdosing
  • AMS
  • analytical chemistry
  • microtracer

FOLLOW TNO ON SOCIAL MEDIA

Stay up to date with our latest news, activities and vacancies

TNO.nl collects and processes data in accordance with the applicable privacy regulations for an optimal user experience and marketing practices.
This data can easily be removed from your temporary profile page at any time.
You can also view our privacy statement or cookie statement.